[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

84

1 MR. VOLVOVITZ: One of the things I think
2 I should add here is that there's going to be bias by
3 whoever looks at the data, whether it's a company
4 president --
5 MR. DOBSON: So why are you wasting our
6 time?
7 MR. VOLVOVITZ: -- or an investigator.
8 MR. DOBSON: So why are you wasting our
9 time with this crap?
10 CO-CHAIRMAN FAUCI: Jesse and Frank, I
11 think we'd better go on.
12 AUDIENCE PARTICIPANT: Just one very
13 quick.
14 CO-CHAIRMAN FAUCI: David? Yes?
15 AUDIENCE PARTICIPANT: You compared the
16 seropositive people for consistency. Are there any
17 comparisons between the gp 160 and the gp 120 in
18 seropositive people?
19 DR. COREY: There is a trial that is
20 currently about ready to be started by the ACTG, ACTG
21 214. It is a comparative trial, Phase II trial, in
22 the same labs at the same time in a randomized schema.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]